Clinical Trials Library
This page is intended to house a list of clinical trials obtained from the database at https://clinicaltrials.gov. This page is updated on a monthly basis with the date of the last update indicated below. If you have additions to this list, please send to info@mced.info
Last updated: 10/10/2023
Multi-Cancer Early Detection (MCED) of Firefighters
URL: https://clinicaltrials.gov/study/NCT05780957
Sponsor/Funder: Vincere Cancer Center
Status: Recruiting
Start Date: 03/21/2023
Completion Date: 12/31/2030
Summary: This study is an observational prospective cohort research study to explore the performance of new blood and urine tests for the early detection of cancer among firefighters.
McfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)
URL: https://clinicaltrials.gov/study/NCT05366881
Sponsor/Funder: Adela, Inc.
Status: Recruiting
Start Date: 05/03/2022
Completion Date: 12/31/2026
Summary: With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be dysregulated during disease
PATHFINDER 2: A Multi-Cancer Early Detection Study
URL: https://clinicaltrials.gov/study/NCT05155605
Sponsor/Funder: GRAIL, LLC
Status: Recruiting
Start Date: 12/8/2021
Completion Date: 7/30/2026
Summary: This is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America. The purpose of this study is to evaluate the safety and performance of the GRAIL MCED test in a population of individuals who are eligible for guideline-recommended cancer screening. In cases with a "cancer signal detected" test result, participants will undergo diagnostic procedures based on the test returned cancer signal origin(s) to determine if they have cancer. The number and types of diagnostic procedures required to achieve diagnostic resolution will be assessed. Participant-reported outcomes will be collected at several time points to assess participants' perceptions about the multi-cancer early detection test.
PERformance of Multi-Cancer Early-Detection Based on Various Biomarkers in fEmale Cancers, PERCEIVE-I
URL:https://classic.clinicaltrials.gov/ct2/show/NCT04903665
Sponsor/Funder: Fudan University
Status: Not Recruiting
Start Date: 03/21/2021
Completion Date: 06/30/2023
Summary: This study is a prospective study aimed to develop and validate the performance of combined multi-omics assays for the early detection of gynecologic cancers. Biomarkers of cfDNA methylation, ctDNA mutation, and blood miRNA markers will be evaluated. The study will enroll approximately 495 female participants, including participants with gynecologic cancers or benign diseases.
PATHFINDER: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
URL: https://clinicaltrials.gov/study/NCT04241796
Sponsor/Funder: GRAIL, LLC
Status: Complete
Start Date: 12/12/2019
Completion Date: 01/05/2022
Summary: PATHFINDER is a prospective, multi-center study in which approximately 6,200 participants will be enrolled. An investigational multi-cancer early detection test, developed by GRAIL, will be ordered by and results returned to a study investigator. In cases with a "signal detected" test result (with a predicted or indeterminate tissue of origin (TOO)), the diagnostic work-up will not be dictated by the protocol, but will instead be coordinated by the ordering and treating medical team at the enrolling sites based on the participant's clinical condition, recommendations by each institution's clinical practices, and in consultation with the study investigator and interdisciplinary care team, as necessary. Additionally, proposed clinical care pathways, developed based on a review of guidelines from the National Comprehensive Cancer Network (NCCN), American College of Radiology (ACR) and other professional organizations, should be referenced by the medical team to determine the diagnostic work-up. The number and types of diagnostic procedures required to achieve diagnostic resolution will be assessed. Performance of multi-cancer early detection test will be evaluated. Additionally, participant-reported outcomes will be collected at several time points to assess participants' perceptions about the multi-cancer early detection test. Participants will be followed for approximately 12 months from the time of enrollment. Cancer status will also be assessed at the 12 month time point.
Project CADENCE (CAncer Detected Early caN be CurEd)
URL: https://clinicaltrials.gov/study/NCT05633342
Sponsor/Funder: MiRXES Pte Ltd
Status: Recruiting
Start Date: 07/07/2022
Completion Date: 05/31/2025
Summary: With existing evidence showing the difference in miRNA expression levels between non-cancer and cancer groups, the investigators assume that levels of DNA methylation, RNA expression as well as protein concentration will also be dysregulated during disease
LEVANTIS-0093A: GAGomes for Multi-Cancer Early Detection in High-Risk Adults
URL: https://clinicaltrials.gov/study/NCT05295017
Sponsor/Funder: Elypta
Status: Recruiting
Start Date: 03/14/2022
Completion Date: 03/31/2025
Summary: LEVANTIS-0093A (LEV93A) is a prospective cohort observational clinical study to validate the plasma free GAGome MCED test in adults at high risk of developing cancer ("high-risk adults"), specifically in 55-80-year-old adults with significant smoking history.
LEV93A will use plasma biospecimens collected within the Yorkshire Lung Screening Trial Biomarker sub-study and corresponding participant data prospectively collected within the Yorkshire Lung Screening Trial (YLST) and the Yorkshire Kidney Screening Trial (YKST) all of which are sponsored by the University of Leeds and funded by Yorkshire Cancer Research (Award references: L403, L403B L403C), in collaboration with the University of Leeds, with the University of Manchester and with the Leeds Teaching Hospitals.
REFLECTION: A Clinical Practice Learning Program for Galleri®
URL: https://clinicaltrials.gov/study/NCT05205967
Sponsor/Funder: GRAIL, LLC
Status: Recruiting
Start Date: 08/23/2021
Completion Date: 08/23/2026
Summary: REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 17,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
URL: https://clinicaltrials.gov/study/NCT03085888
Sponsor/Funder: GRAIL, LLC
Status: Not Recruiting
Start Date: 02/28/2017
Completion Date: 05/30/2025
Summary: GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to validate the ability of the pre-specified GRAIL Test to detect breast cancer and other invasive cancers, including hematologic malignancies, that will occur within one year of the first study blood draw.
Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
URL: https://clinicaltrials.gov/study/NCT05227534
Sponsor/Funder: Guangzhou Burning Rock Dx Co., Ltd.
Status: Recruiting
Start Date: 06/01/2022
Completion Date: 12/31/2028
Summary: PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
LEVANTIS-0087A: GAGomes for Multi-Cancer Early Detection in Asymptomatic Adults
URL: https://clinicaltrials.gov/study/NCT05235009
Sponsor/Funder: Elypta
Status: Recruiting
Start Date: 02/01/2022
Completion Date: 03/31/2025
Summary: LEVANTIS-0087A (LEV87A) is a retrospective in vitro diagnostics clinical validation population cohort-based case-control study to validate the diagnostic performance of free GAGome-based tests for multi-cancer early detection (MCED) in adults asymptomatic for cancer and with no recent history of cancer.
Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique project (PRESCIENT)
URL: https://clinicaltrials.gov/study/NCT04822792
Sponsor/Funder: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: Unknown
Start Date: 03/23/2021
Completion Date: 06/30/2023
Summary: PRESCIENT is a multi-center, prospective observational study aimed to detect cancers early by combined assays for serum protein markers and cell-free DNA (cfDNA) methylation markers. Blood RNA markers will also be evaluated. The study will enroll approximately 11879 participants, including participants with malignancies or benign diseases, and healthy participants.